Bio-Techne Corp
NASDAQ:TECH

Watchlist Manager
Bio-Techne Corp Logo
Bio-Techne Corp
NASDAQ:TECH
Watchlist
Price: 53.67 USD 0.13% Market Closed
Market Cap: 8.4B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
+2%
Operating Income
Forecast
N/A
Net Income
Forecast
+67%

Wall Street
Price Targets

TECH Price Targets Summary
Bio-Techne Corp

Wall Street analysts forecast TECH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TECH is 68.1 USD with a low forecast of 55.55 USD and a high forecast of 87.15 USD.

TECH Lowest Forecast
Wall Street Target
55.55 USD
4% Upside
TECH Average Forecast
Wall Street Target
68.1 USD
27% Upside
TECH Highest Forecast
Wall Street Target
87.15 USD
62% Upside
Lowest
Price Target
55.55 USD
4% Upside
Average
Price Target
68.1 USD
27% Upside
Highest
Price Target
87.15 USD
62% Upside
Bio-Techne Corp Competitors:
Price Targets
ICLR
ICON PLC
24% Upside
ONT
Oxford Nanopore Technologies PLC
11% Downside
O
ONESOURCE
Onesource Specialty Pharma Ltd
27% Upside
TMO
Thermo Fisher Scientific Inc
15% Upside
ICLR
ICON PLC
24% Upside
ONT
Oxford Nanopore Technologies PLC
11% Downside
O
ONESOURCE
Onesource Specialty Pharma Ltd
27% Upside
TMO
Thermo Fisher Scientific Inc
15% Upside
AZTA
Azenta Inc
7% Upside
MTD
Mettler-Toledo International Inc
1% Downside

Revenue
Forecast

Revenue Estimate
Bio-Techne Corp

For the last 8 years the compound annual growth rate for Bio-Techne Corp's revenue is 11%. The projected CAGR for the next 4 years is 7%.

11%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-2%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Bio-Techne Corp

For the last 8 years the compound annual growth rate for Bio-Techne Corp's operating income is 6%. The projected CAGR for the next 4 years is 20%.

6%
Past Growth
20%
Estimated Growth
Estimates Accuracy
-30%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Bio-Techne Corp

For the last 8 years the compound annual growth rate for Bio-Techne Corp's net income is 6%. The projected CAGR for the next 4 years is 25%.

6%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-29%
Average Miss
What are analyst estimates?

See Also

Summary
TECH intrinsic value, competitors valuation, and company profile.
DCF Valuation
TECH stock valuation using Discount Cash Flow valuation method.
Relative Valuation
TECH stock valuation using valuation multiples.
Wall Street Estimates
TECH price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
TECH stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is TECH's stock price target?
Price Target
68.1 USD

According to Wall Street analysts, the average 1-year price target for TECH is 68.1 USD with a low forecast of 55.55 USD and a high forecast of 87.15 USD.

What is Bio-Techne Corp's Revenue forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Bio-Techne Corp's revenue is 11%. The projected CAGR for the next 4 years is 7%.

What is Bio-Techne Corp's Operating Income forecast?
Projected CAGR
20%

For the last 8 years the compound annual growth rate for Bio-Techne Corp's operating income is 6%. The projected CAGR for the next 4 years is 20%.

What is Bio-Techne Corp's Net Income forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Bio-Techne Corp's net income is 6%. The projected CAGR for the next 4 years is 25%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 276,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.